EAM
SPRY icon

Eventide Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Eventide Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-371,384
Closed -$11.5M – 161
2021
Q2 		$11.5M Hold
371,384
– – 0.15% 114
2021
Q1 		$16.2M Buy
371,384
+29,911
+9% +$1.42M 0.24% 99
2020
Q4 		$15.8M Buy
+341,473
New +$11.4M 0.24% 98

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eventide Asset Management's SPRY Position: Q3 2021 in Review

Eventide Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2021, closing a stake of 371,384 shares — an estimated $11.5M sold.

Eventide Asset Management first reported a position in SPRY in Q4 2020 and held it in 3 quarters. The position peaked at $16.2M in Q1 2021. 74 funds tracked by Wall St. Rank hold SPRY as of Q3 2021.

  • Eventide Asset Management reported no remaining ARS Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Eventide Asset Management sold 371,384 ARS Pharmaceuticals shares in Q3 2021, an estimated $11.5M.
  • Eventide Asset Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Eventide Asset Management's ARS Pharmaceuticals position peaked at $16.2M in Q1 2021.
  • 74 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2021.

Based on Eventide Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.